German Cll Study Group
Clinical trials sponsored by German Cll Study Group, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Massive new registry to track thousands of blood cancer patients for years Results expected Dec 2026 (estimated)
- Can a Four-Drug cocktail erase traces of Hard-to-Treat leukemia? Results expected Feb 2027 (estimated)
- Can three targeted drugs tame an aggressive blood cancer? Results expected Aug 2027 (estimated)
- Major CLL trial tests which drug combo works best for new patients Results expected Sep 2027 (estimated)
-
Can a Four-Drug cocktail erase traces of Hard-to-Treat leukemia?
Disease control OngoingThis phase 2 trial is testing whether a sequence of four drugs—bendamustine, obinutuzumab, zanubrutinib, and venetoclax—can eliminate minimal residual disease in people with relapsed or refractory chronic lymphocytic leukemia (CLL). The study enrolls about 42 adults whose CLL has…
Phase 2 • Sponsor: German CLL Study Group • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Major CLL trial tests which drug combo works best for new patients
Disease control OngoingThis phase 3 trial compares three treatment approaches for people with previously untreated chronic lymphocytic leukemia (CLL): continuous ibrutinib alone, a fixed-duration combination of venetoclax plus obinutuzumab, or a fixed-duration combination of ibrutinib plus venetoclax. …
Phase 3 • Sponsor: German CLL Study Group • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC